Fundraising FoxSante Health Ventures — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Molecular TemplatesinJul 2023SEC filinghigh confidence
Focused on Engineered Toxin Bodies immunotoxins for cancer treatment.
BiotechAustin, US
Eric E. Poma(Executive Officer, Director)Jason S. Kim(Executive Officer)David R. Hoffmann(Director)David Hirsch(Director)David Valacer(Executive Officer)Harold Selick(Director)
Board seatKevin LalandeKevin M. Lalande· per SEC Form D · $90.7M raise · filed Jul 2023
Co-investorsLongitude CapitalExcel Venture Management
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.